Impact of oncometabolites on prostate cancer progression and prognosis Due to the impact of oncometabolites in cancers, different studies have been focused on their role in prostate cancer (Table 1)
Fuselier T, Mota de Sa P, Qadir MMF, Xu B, Allard C, Meyers MM, et al
10.3389/fphys.2023.1231621 95
One of these GLP-1RAs is liraglutide, approved in 2010 and marketed by Novo Nordisk in two formulations: Victoza for diabetes treatment and Saxenda for weight loss
Combination with Other Treatments: Glutathione can be combined with other aesthetic treatments such as skin peels, laser therapies, or mesotherapy for enhanced results
If Congress or CMS chooses not to extend the program past 2027, patient access could lapse, potentially reversing the health improvements achieved during the program